These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31292013)

  • 21. IMPACT OF HEALTH TECHNOLOGY ASSESSMENT IN LITIGATION CONCERNING ACCESS TO HIGH-COST DRUGS.
    Aleman A; Perez Galan A
    Int J Technol Assess Health Care; 2017 Jan; 33(4):411-414. PubMed ID: 28756785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of a policy dialogue to facilitate evidence-informed policy development for improved access to care: the case of the Winnipeg Central Intake Service (WCIS).
    Damani Z; MacKean G; Bohm E; DeMone B; Wright B; Noseworthy T; Holroyd-Leduc J; Marshall DA
    Health Res Policy Syst; 2016 Oct; 14(1):78. PubMed ID: 27756401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OVERCOMING THE BARRIERS TO ACHIEVING UNIVERSAL HEALTH CARE IN THE ASIAN REGION.
    Mundy L; Trowman R; Kearney B
    Int J Technol Assess Health Care; 2018 Jan; 34(4):352-359. PubMed ID: 29986782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accessing public healthcare in Oslo, Norway: the experiences of Thai immigrant masseuses.
    Tschirhart N; Diaz E; Ottersen T
    BMC Health Serv Res; 2019 Oct; 19(1):722. PubMed ID: 31638984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More than cost-effectiveness? Applying a second-stage filter to improve policy decision making.
    Kan K; Jörg F; Lokkerbol J; Mihalopoulos C; Buskens E; Schoevers RA; Feenstra TL
    Health Expect; 2021 Aug; 24(4):1413-1423. PubMed ID: 34061430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
    Gold R; Toumi M; Meesen B; Fogarty E
    Mult Scler; 2016 Aug; 22(2 Suppl):60-70. PubMed ID: 27465616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health care technology in the United Kingdom.
    Spiby J
    Health Policy; 1994; 30(1-3):295-334. PubMed ID: 10139494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying challenges and barriers in the delivery of primary healthcare at the district level: a study in one Thai province.
    Tejativaddhana P; Briggs D; Fraser J; Minichiello V; Cruickshank M
    Int J Health Plann Manage; 2013; 28(1):16-34. PubMed ID: 22696117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence informed decision making: the use of "colloquial evidence" at nice.
    Sharma T; Choudhury M; Kaur B; Naidoo B; Garner S; Littlejohns P; Staniszewska S
    Int J Technol Assess Health Care; 2015 Jan; 31(3):138-46. PubMed ID: 25991028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What systems participants know about access and service entry and why managers should listen.
    Duncombe R
    Aust Health Rev; 2017 Aug; 41(4):449-454. PubMed ID: 27567975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Institute for Quality and Efficiency in Health Care: Germany.
    Nasser M; Sawicki P
    Issue Brief (Commonw Fund); 2009 Jul; 57():1-12. PubMed ID: 19639711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining the Benefit Package of Thailand Universal Coverage Scheme: From Pragmatism to Sophistication.
    Tangcharoensathien V; Patcharanarumol W; Suwanwela W; Supangul S; Panichkriangkrai W; Kosiyaporn H; Witthayapipopsakul W
    Int J Health Policy Manag; 2020 Apr; 9(4):133-137. PubMed ID: 32331492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between a Centrally Reimbursed Fee Schedule Policy and Access to Cataract Surgery in the Universal Coverage Scheme in Thailand.
    Limwattananon C; Limwattananon S; Tungthong J; Sirikomon K
    JAMA Ophthalmol; 2018 Jul; 136(7):796-802. PubMed ID: 29800002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social and ethical analysis in health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S81-6. PubMed ID: 24964703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.